{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:25:54Z","timestamp":1788193554880,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Monthly headache frequency directly correlates with personal\/societal burden and impacts severity and preventive treatment decisions. This post hoc analysis identified shifts from higher to lower frequency headache categories over 6\u00a0months in patients with migraine participating in the PROMISE clinical trials receiving two eptinezumab doses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Headache frequency at baseline and over study months 1\u20136 was categorized into 4 groups: chronic migraine (CM;\u2009\u2265\u200915 monthly headache days [MHDs]), high-frequency episodic migraine (HFEM; 10\u201314 MHDs), low-frequency episodic migraine (LFEM; 4\u20139 MHDs), and\u2009\u2264\u20093 MHDs. Outcomes included the percentage of patients within each MHD category, the percentage of patients improving by\u2009\u2265\u20091 MHD category, and the number of months with reduction of\u2009\u2265\u20091 MHD category. Data from patients who received approved eptinezumab doses (100\u00a0mg or 300\u00a0mg) or placebo were included.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean headache frequency at baseline in PROMISE-1 was 10 MHDs; most patients were classified as having HFEM (48.6%) or LFEM (43.9%). At Month 1, 62\/221 (28.1%), 75\/222 (33.8%), and 45\/222 (20.3%) patients who received eptinezumab 100\u00a0mg, 300\u00a0mg, and placebo had\u2009\u2264\u20093 MHDs, with 97\/221 (43.9%), 108\/222 (48.6%), and 84\/222 (37.8%), respectively, falling below the diagnostic EM threshold at Month 6. More than one-third (79\/221 [35.7%], 83\/222 [37.4%], and 68\/222 [30.6%] of patients in the eptinezumab 100\u00a0mg, 300\u00a0mg, and placebo groups, respectively), had 6\u00a0months of reduction of\u2009\u2265\u20091 frequency category. At baseline in PROMISE-2, mean headache frequency was 20.5 MHDs. All patients (100%) in the eptinezumab 100\u00a0mg and placebo groups had CM, as did 99.4% of patients receiving eptinezumab 300\u00a0mg. At Month 1, 209\/356 (58.7%), 216\/350 (61.7%), and 167\/366 (45.6%) patients treated with eptinezumab 100\u00a0mg, 300\u00a0mg, and placebo had\u2009\u2264\u200914 MHDs, with 240\/356 (67.4%), 249\/350 (71.1%), and 221\/366 (60.4%), respectively, falling below CM threshold at Month 6. Additionally, 153\/356 (43.0%), 169\/350 (48.3%), and 116\/366 (31.7%) patients in the eptinezumab 100\u00a0mg, 300\u00a0mg, and placebo groups, respectively, had 6\u00a0months of reduction of\u2009\u2265\u20091 frequency category.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the PROMISE studies, episodic and chronic migraine patients treated with eptinezumab were more likely to reduce their headache frequency versus placebo, which directly and in a sustained way improved their diagnostic category classification.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov Identifier: NCT02559895, NCT02974153.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-02914-9","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T07:03:09Z","timestamp":1666681389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies"],"prefix":"10.1186","volume":"22","author":[{"given":"Patricia","family":"Pozo-Rosich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Dodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Ettrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Hirman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Cady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"2914_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1212\/01.wnl.0000325565.63526.d2","volume":"71","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. Neurol. 2008;71:848\u201355. https:\/\/doi.org\/10.1212\/01.wnl.0000325565.63526.d2.","journal-title":"Neurol"},{"key":"2914_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18:101. https:\/\/doi.org\/10.1186\/s10194-017-0787-1.","journal-title":"J Headache Pain"},{"key":"2914_CR3","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1111\/HEAD.13966","volume":"60","author":"DC Buse","year":"2020","unstructured":"Buse DC, Reed ML, Fanning KM, et al. Demographics, headache features, and comorbidity profiles in relation to headache frequency in people with migraine: results of the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2020;60:2340\u201356. https:\/\/doi.org\/10.1111\/HEAD.13966.","journal-title":"Headache"},{"key":"2914_CR4","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML, et al. Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2019;59:1286\u201399. https:\/\/doi.org\/10.1111\/head.13613.","journal-title":"Headache"},{"key":"2914_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-020-1084-y","volume":"21","author":"DC Buse","year":"2020","unstructured":"Buse DC, Reed ML, Fanning KM, et al. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2020;21:23. https:\/\/doi.org\/10.1186\/s10194-020-1084-y.","journal-title":"J Headache Pain"},{"key":"2914_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/0333102416636055","volume":"37","author":"M Torres-Ferr\u00fas","year":"2017","unstructured":"Torres-Ferr\u00fas M, Quintana M, Fernandez-Morales J, et al. When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia. 2017;37:104\u201313. https:\/\/doi.org\/10.1177\/0333102416636055.","journal-title":"Cephalalgia"},{"key":"2914_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"AM Blumenfeld","year":"2011","unstructured":"Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31:301\u201315. https:\/\/doi.org\/10.1177\/0333102410381145.","journal-title":"Cephalalgia"},{"key":"2914_CR8","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1111\/head.13421","volume":"58","author":"SD Silberstein","year":"2018","unstructured":"Silberstein SD, Lee L, Gandhi K, et al. Health care resource utilization and migraine disability along the migraine continuum among patients treated for migraine. Headache. 2018;58:1579\u201392. https:\/\/doi.org\/10.1111\/head.13421.","journal-title":"Headache"},{"key":"2914_CR9","unstructured":"National Headache Foundation Position Statement on the Treatment of Migraine and Access to Care. National Headache Foundation;\u00a02022. https:\/\/headaches.org\/national-headache-foundation-position-statement-on-the-treatment-of-migraine\/. Accessed 28\u00a0Feb\u00a02022."},{"key":"2914_CR10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1017\/S031716710001516X","volume":"39","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Davenport W, Mackie G, et al. Canadian headache society guideline for migraine prophylaxis. Can J Neurol Sci. 2012;39:S1-59.","journal-title":"Can J Neurol Sci"},{"key":"2914_CR11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS. The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021\u201339. https:\/\/doi.org\/10.1111\/head.14153.","journal-title":"Headache"},{"key":"2914_CR12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1212\/CON.0000000000000199","volume":"21","author":"SD Silberstein","year":"2015","unstructured":"Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21:973\u201389. https:\/\/doi.org\/10.1212\/CON.0000000000000199.","journal-title":"Continuum (Minneap Minn)"},{"key":"2914_CR13","unstructured":"Vyepti [package insert]. Lundbeck Seattle BioPharmaceuticals Inc; 2021."},{"key":"2914_CR14","unstructured":"Vyepti [EMA Authorization]. Lundbeck A\/S Valby, Denmark; 2021."},{"key":"2914_CR15","unstructured":"Product Monograph Including Patient\nMedication Information: Vyepti (Eptinezumab for injection). Lundbeck Canada Inc;\u00a02021."},{"key":"2914_CR16","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1177\/0333102419858355","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia. 2019;39:1075\u201385. https:\/\/doi.org\/10.1177\/0333102419858355.","journal-title":"Cephalalgia"},{"key":"2914_CR17","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurol. 2020;94:e1365\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169.","journal-title":"Neurol"},{"key":"2914_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40:241\u201354. https:\/\/doi.org\/10.1177\/0333102420905132.","journal-title":"Cephalalgia"},{"key":"2914_CR19","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.clinthera.2020.11.007","volume":"42","author":"TR Smith","year":"2020","unstructured":"Smith TR, Janelidze M, Chakhava G, et al. Eptinezumab for the prevention of episodic migraine: sustained effect through 1 year of treatment in the PROMISE-1 study. Clin Ther. 2020;42:2254-2265.e3. https:\/\/doi.org\/10.1016\/j.clinthera.2020.11.007.","journal-title":"Clin Ther"},{"key":"2914_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01186-3","volume":"21","author":"S Silberstein","year":"2020","unstructured":"Silberstein S, Diamond M, Hindiyeh NA, et al. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy\u20132) study. J Headache Pain. 2020;21:1\u201312. https:\/\/doi.org\/10.1186\/s10194-020-01186-3.","journal-title":"J Headache Pain"},{"key":"2914_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","volume":"21","author":"D Kudrow","year":"2021","unstructured":"Kudrow D, Cady RK, Allan B, et al. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol. 2021;21:126. https:\/\/doi.org\/10.1186\/s12883-021-02123-w.","journal-title":"BMC Neurol"},{"key":"2914_CR22","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1001\/jama.2021.7665","volume":"325","author":"PK Winner","year":"2021","unstructured":"Winner PK, McAllister P, Chakhava G, et al. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA. 2021;325:2348\u201356. https:\/\/doi.org\/10.1001\/jama.2021.7665.","journal-title":"JAMA"},{"key":"2914_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-021-01227-5","volume":"22","author":"TR Smith","year":"2021","unstructured":"Smith TR, Spierings ELH, Cady R, et al. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain. 2021;22:1\u201311. https:\/\/doi.org\/10.1186\/s10194-021-01227-5.","journal-title":"J Headache Pain"},{"key":"2914_CR24","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/head.14007","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Gottschalk C, Cady R, et al. Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on Day 1 after dosing. Headache. 2020;60:2220\u201331. https:\/\/doi.org\/10.1111\/head.14007.","journal-title":"Headache"},{"key":"2914_CR25","doi-asserted-by":"publisher","first-page":"8286","DOI":"10.1038\/s41598-021-87352-2","volume":"11","author":"P Irimia","year":"2021","unstructured":"Irimia P, Garrido-Cumbrera M, Santos-Lasaosa S, et al. Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas. Sci Rep. 2021;11:8286. https:\/\/doi.org\/10.1038\/s41598-021-87352-2.","journal-title":"Sci Rep"},{"key":"2914_CR26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.clinthera.2022.01.006","volume":"44","author":"V Martin","year":"2022","unstructured":"Martin V, Nagy AJ, Janelidze M, et al. Impact of baseline characteristics on the efficacy and safety of Eptinezumab in patients with migraine: subgroup analyses of PROMISE-1 and PROMISE-2. Clin Ther. 2022;44:389\u2013402. https:\/\/doi.org\/10.1016\/j.clinthera.2022.01.006.","journal-title":"Clin Ther"},{"key":"2914_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S10194-022-01387-Y\/FIGURES\/5","volume":"23","author":"DC Buse","year":"2022","unstructured":"Buse DC, Winner PK, Charleston L, et al. Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine. J Headache Pain. 2022;23:1\u201312. https:\/\/doi.org\/10.1186\/S10194-022-01387-Y\/FIGURES\/5.","journal-title":"J Headache Pain"},{"key":"2914_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update. J Headache Pain. 2022;23:67. https:\/\/doi.org\/10.1186\/s10194-022-01431-x.","journal-title":"J Headache Pain"},{"key":"2914_CR29","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1177\/03331024221089567","volume":"42","author":"P McAllister","year":"2022","unstructured":"McAllister P, Kudrow D, Cady R, et al. Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine. Cephalalgia. 2022;42:1005. https:\/\/doi.org\/10.1177\/03331024221089567.","journal-title":"Cephalalgia"},{"key":"2914_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/S40120-020-00196-2\/TABLES\/3","volume":"9","author":"MJ Doane","year":"2020","unstructured":"Doane MJ, Gupta S, Fang J, et al. The humanistic and economic burden of migraine in Europe: a cross-sectional survey in five countries. Neurol Ther. 2020;9:535\u201349. https:\/\/doi.org\/10.1007\/S40120-020-00196-2\/TABLES\/3.","journal-title":"Neurol Ther"},{"key":"2914_CR31","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/head.12332","volume":"54","author":"RB Lipton","year":"2014","unstructured":"Lipton RB, Serrano D, Pavlovic JM, et al. Improving the classification of migraine subtypes: an empirical approach based on factor mixture models in the american migraine prevalence and prevention (AMPP) study. Headache. 2014;54:830\u201349. https:\/\/doi.org\/10.1111\/head.12332.","journal-title":"Headache"},{"key":"2914_CR32","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1111\/head.12164","volume":"53","author":"D Serrano","year":"2013","unstructured":"Serrano D, Buse DC, Kori SH, et al. Effects of switching acute treatment on disability in migraine patients using triptans. Headache: J Head Face Pain. 2013;53:1419. https:\/\/doi.org\/10.1111\/head.12164.","journal-title":"Headache: J Head Face Pain"},{"key":"2914_CR33","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1007\/s00415-021-10715-2","volume":"269","author":"E Caronna","year":"2022","unstructured":"Caronna E, Gallardo VJ, Alpuente A, et al. Epidemiology, work and economic impact of migraine in a large hospital cohort: time to raise awareness and promote sustainability. J Neurol. 2022;269:1456\u201362. https:\/\/doi.org\/10.1007\/s00415-021-10715-2.","journal-title":"J Neurol"},{"key":"2914_CR34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0333102410383590","volume":"31","author":"Z Katsarava","year":"2011","unstructured":"Katsarava Z, Manack A, Yoon M-S, et al. Chronic migraine: classification and comparisons. Cephalalgia. 2011;31:520\u20139. https:\/\/doi.org\/10.1177\/0333102410383590.","journal-title":"Cephalalgia"},{"key":"2914_CR35","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/head.14154","volume":"61","author":"R Ishii","year":"2021","unstructured":"Ishii R, Schwedt TJ, Dumkrieger G, et al. Chronic versus episodic migraine: The 15\u2010day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache: J Head and Face Pain. 2021;61:992\u20131003. https:\/\/doi.org\/10.1111\/head.14154.","journal-title":"Headache: J Head and Face Pain"},{"key":"2914_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/S10194-022-01418-8","volume":"23","author":"R Apelian","year":"2022","unstructured":"Apelian R, Boyle L, Hirman J, Asher D. Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2. J Headache Pain. 2022;23:48. https:\/\/doi.org\/10.1186\/S10194-022-01418-8.","journal-title":"J Headache Pain"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02914-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02914-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02914-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T19:14:45Z","timestamp":1666725285000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02914-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2914"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02914-9","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]},"assertion":[{"value":"9 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The PROMISE-1 study was approved by the independent ethics committee or institutional review board for each of the 87 study sites: Birmingham, Alabama, United States, 35216; Phoenix, Arizona, United States, 85013; Tucson, Arizona, United States, 85712; Little Rock, Arkansas, United States, 72205; Anaheim, California, United States, 92801; Fresno, California, United States, 93702; Fullerton, California, United States, 92835; Long Beach, California, United States, 90806; Montclair, California, United States, 91763; Oceanside, California, United States, 92056; Redlands, California, United States, 92374; two sites in San Diego, California, United States: 92103; 92108; Santa Monica, California, United States, 90404; Sherman Oaks, California, United States, 91403; Colorado Springs, Colorado, United States, 80918; Fort Collins, Colorado, United States, 80528; Stamford, Connecticut, United States, 06905; Waterbury, Connecticut, United States, 06708; Bradenton, Florida, United States, 34201; DeLand, Florida, United States, 32720; Fort Myers, Florida, United States, 33912; Hallandale Beach, Florida, United States, 33009; Hialeah, Florida, United States, 33012; Maitland, Florida, United States, 32751; three sites in Miami, Florida, United States: 33143; 33155; 33173; Naples, Florida, United States, 34102; Orlando, Florida, United States, 32801; Sunrise, Florida, United States, 33351; Winter Haven, Florida, United States, 33880; two sites in Atlanta, Georgia, United States: 30331; 30342; Stockbridge, Georgia, United States, 30281; Chicago, Illinois, United States, 60607; Lisle, Illinois, United States, 60532; Prairie Village, Kansas, United States, 66206; Lexington, Kentucky, United States, 40509; Owensboro, Kentucky, United States, 42303; New Orleans, Louisiana, United States, 70115; Boston, Massachusetts, United States, 02131; North Attleboro, Massachusetts, United States, 02760; Springfield, Massachusetts, United States, 01104; Watertown, Massachusetts, United States, 02472; Ann Arbor, Michigan, United States, 48104; Farmington Hills, Michigan, United States, 48334; Jackson, Michigan, United States, 49201; Minneapolis, Minnesota, United States, 55402; Flowood, Mississippi, United States, 39232; Saint Louis, Missouri, United States, 63141; Springfield, Missouri, United States, 65807; Las Vegas, Nevada, United States, 89119; Reno, Nevada, United States, 89502; Albuquerque, New Mexico, United States, 87102; two sites in Brooklyn, New York, United States: 11213; 11229; Hartsdale, New York, United States, 10530; Rochester, New York, United States, 14609; Staten Island, New York, United States, 10312; Durham, North Carolina, United States, 27713; Greensboro, North Carolina, United States, 27405; High Point, North Carolina, United States, 27265; Wilmington, North Carolina, United States, 28401; Dayton, Ohio, United States, 45424; Edmond, Oklahoma, United States, 73034; Norman, Oklahoma, United States, 73069; Oklahoma City, Oklahoma, United States, 73112; Portland, Oregon, United States, 97210; Allentown, Pennsylvania, United States, 18104; Smithfield, Pennsylvania, United States, 15478; Anderson, South Carolina, United States, 29621; two sites in Chattanooga, Tennessee, United States: 37404; 37421; Kingsport, Tennessee, United States, 37660; Memphis, Tennessee, United States, 38119; Austin, Texas, United States, 78745; Dallas, Texas, United States, 75231; two sites in Houston, Texas, United States: 77074; 77081; Richmond, Virginia, United States, 23294; Virginia Beach, Virginia, United States, 23454; Bellevue, Washington, United States, 98007; and four sites in Tbilisi, Georgia: 0112; 0160; 0179; 0186. The PROMISE-2 study was approved by the independent ethics committee or institutional review board for each of the 145 study sites: Birmingham, Alabama, United States, 35235; Phoenix, Arizona, United States, 85032; Little Rock, Arkansas, United States, 72211; Carlsbad, California, United States, 92011; Oceanside, California, United States, 92056; Orange, California, United States, 92868; Oxnard, California, United States, 93030; Palo Alto, California, United States, 94304; Redlands, California, United States, 92374; San Diego, California, United States, 92108; Santa Monica, California, United States, 90404; Torrance, California, United States, 90502; Colorado Springs, Colorado, United States, 80918; New London, Connecticut, United States, 06320; Jacksonville, Florida, United States, 32256; Miami, Florida, United States, 33155; Orlando, Florida, United States, 32806; Tampa, Florida, United States, 33606; West Palm Beach, Florida, United States, 33407; Winter Haven, Florida, United States, 33880; two sites in Atlanta, Georgia, United States: 30328; 30342; Decatur, Georgia, United States, 30030; Champaign, Illinois, United States, 61820; two sites in Chicago, Illinois, United States: 60607; 60642; Anderson, Indiana, United States, 46011; Des Moines, Iowa, United States, 50309; Overland Park, Kansas, United States, 66212; Prairie Village, Kansas, United States, 66208; Wichita, Kansas, United States, 67207; Marrero, Louisiana, United States, 70072; Waldorf, Maryland, United States, 20603; Boston, Massachusetts, United States, 02135; North Attleboro, Massachusetts, United States, 02740; Watertown, Massachusetts, United States, 02472; Ann Arbor, Michigan, United States, 48104; Minneapolis, Minnesota, United States, 55402; Flowood, Mississippi, United States, 39232; Saint Louis, Missouri, United States, 63141; Saint Peters, Missouri, United States, 63303; Springfield, Missouri, United States, 65810; Las Vegas, Nevada, United States, 89113; Lebanon, New Hampshire, United States, 03756; Princeton, New Jersey, United States, 08540; Albuquerque, New Mexico, United States, 87102; Amherst, New York, United States, 14226; Brooklyn, New York, United States, 11229; two sites in New York, New York, United States: 10016; 10019; Plainview, New York, United States, 11803; Rochester, New York, United States, 14609; Durham, North Carolina, United States, 27705; High Point, North Carolina, United States, 27262; Canton, Ohio, United States, 44718; Dayton, Ohio, United States, 45432; Oklahoma City, Oklahoma, United States, 73116; Scottdale, Pennsylvania, United States, 15683; Smithfield, Pennsylvania, United States, 15478; Mount Pleasant, South Carolina, United States, 29464; two sites in Chattanooga, Tennessee, United States: 37404; 37421; Memphis, Tennessee, United States, 38119; Nashville, Tennessee, United States, 37203; Dallas, Texas, United States, 75214; Houston, Texas, United States, 77058; Houston, Texas, United States, 77081; North Richland Hills, Texas, United States, 76180; San Antonio, Texas, United States, 78258; two sites in Salt Lake City, Utah, United States: 84109; 84123; Richmond, Virginia, United States, 23294; Bellevue, Washington, United States, 98007; Spokane, Washington, United States, 99202; Brussels, Belgium, 1090; two sites in Liege, Belgium, 4000; Brno, Czechia, 61500; Choce\u0148, Czechia, 565 01; Prague, Czechia, 18200; Praha, Czechia, 100 34; Glostrup, Denmark, 2600; Viborg, Denmark, 8800; four sites in Tbilisi, Georgia: 0112; 0160; 0179; 0186; Berlin, Germany, 10117; Erlangen, Germany, 91054; Hamburg, Germany, 20246; Nordheim, Germany, 45122; Unterhaching, Germany, 82008; three sites in Budapest, Hungary: 1033; 1083; 1145; Pecs, Hungary, 7623; Ancona, Italy, 60020; two sites in Milano, Italy: 20132; 20133; Napoli, Italy, 80131; Pavia, Italy, 27100; Roma, Italy, 00163; Ekaterinburg, Russian Federation, 620102; Kazan', Russian Federation, 420064; Krasnoyarsk, Russian Federation, 660037Moscow, Russian Federation, 121467; two sites in Novosibirsk, Russian Federation, 630051; 630054; three sites in Saint Petersburg, Russian Federation: 191144; 194044; 194223; Yaroslavl', Russian Federation, 150030; Banska Bystrica, Slovakia, 97404Doln\u00fd Kub\u00edn, Slovakia, 026 01; Dubnica nad Vahom, Slovakia, 01841; Krompachy, Slovakia, 053 42; Alicante, Spain, 03010; Barcelona, Spain, 08035; Guadalajara, Spain, 19002; Lleida, Spain, 25198; four sites in Madrid, Spain: 28046; 28050; 28222; 28223; Navarr\u00e9s, Spain, 31008; Santander, Spain, 39008; Sevilla, Spain, 41013; Terrassa, Spain, 08221; Valencia, Spain, 46026; Valladolid, Spain, 47005; two sites in Dnipropetrovs'k, Ukraine: 49045; 49027; Ivano-Frankivs'k, Ukraine, 76008; two sites in Kharkiv, Ukraine: 61068; 61103; L'viv, Ukraine, 79010; Odessa, Ukraine, 65014; Vinnytsia, Ukraine, 21005; Zaporizhzhya, Ukraine, 69065; Glasgow, United Kingdom, G51 4TF; Inverness, United Kingdom, IV2 3UJ; London, United Kingdom, SE5 9PL; Newcastle, United Kingdom, NE1 4LP; Salford, United Kingdom, M8 8HD; and Stoke-on-Trent, United Kingdom, ST4 7LN. Both studies were conducted in accordance with standards of Good Clinical Practice as defined by the International Conference on Harmonisation and all applicable federal and local regulations. All study documentation was approved by the local review board at each site or by a central institutional review board or ethics committee. All patients provided written informed consent prior to participation in their respective study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PP-R has received honoraria as a consultant and speaker from Allergan\/AbbVie, Biohaven, Chiesi, Eli Lilly, Medscape, Lundbeck, Novartis, and Teva Pharmaceuticals. Her research group has received research grants from AGAUR, Allergan\/AbbVie, EraNet Migraine Research Foundation, FEDER RIS3CAT, Instituto Investigaci\u00f3n Carlos III, International Headache Society, la Caixa foundation, MICINN, Neuron, Novartis, PERIS, and Teva; and has received funding for clinical trials from Alder, Allergan\/AbbVie, Amgen, electroCore, Eli Lilly, Lundbeck, Novartis, and Teva. She is the Honorary Secretary of the International Headache Society. She is on the editorial board of <i>Revista de Neurologia<\/i>. She is an associate editor for <i>Cephalalgia<\/i>, <i>Headache<\/i>, <i>Neurologia,<\/i> and <i>Frontiers of Neurology<\/i> and an advisory Scientific member of the Editorial Board of <i>The Journal of Headache and Pain.<\/i> She is a member of the Clinical Trials Guidelines Committee and Scientific Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She is the founder of . PP-R does not own stocks from any pharmaceutical company.DD has been a consultant for Amgen, Allergan\/Abbvie, Atria Health, AYYA Biosciences, Biohaven, CapiThera Ltd., Cerecin, Ceruvia Lifesciences LLC, Cooltech, Ctrl M, Eli Lilly, GSK, Impel, Lundbeck, Nocira, Novartis, Perfood, Pfizer, Praxis, Revance, Satsuma, Theranica, and WL Gore. He has received payment or honoraria from Amgen, Allergan\/Abbvie, Biohaven, Cambridge University Press, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Eli Lilly, Global Access Meetings, KLJ Associates, Lundbeck, Majallin LLC, Medlogix Communications, Miller Medical Communications, MJH Lifesciences, Novartis, Oxford University Press, Pfizer, Vector Psychometric Group, WebMD Health\/Medscape, and Wolters Kluwer. He has participated on Data Safety Monitoring or Advisory Boards for Allergan\/Abbvie, Academy for Continued Healthcare Learning, Amgen, and Biohaven. He has received research support from American Migraine Foundation, Department of Defense, Henry Jackson Foundation, National Institutes of Health, Patient Centered Outcomes Research Institute (PCORI), and Sperling Foundation. He has a leadership or fiduciary role with American Brain Foundation, American Migraine Foundation, International Headache Society, and Global Patient Advocacy Coalition. He owns stock or stock options in Atria Health, Aural Analytics, AYYA Biosciences, Epien, ExSano, Healint, King-Devick Technologies, Man and Science, Matterhorn, Nocira, Ontologics, Precon Health, Second Opinion\/Mobile Health, and Theranica. He holds a patent, 17189376.1\u20131466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis without fee, and has a patent application submitted, Synaquell (Precon Health). AE is a full-time employee of H. Lundbeck A\/S. JH is an employee of Pacific Northwest Statistical Consulting, Inc., a contracted service provider of biostatistical resources for Lundbeck. RC was an employee of Lundbeck at the time of manuscript development.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"394"}}